Medical Technology

Antibody Protection From Mild COVID-19 May Not Last

(Reuters) – Nearly everyone who had a mild case of COVID-19 still has antibodies to the coronavirus a year later, but that might not protect them from new variants circulating now, a small study suggests.

Among 43 Australians who dealt with mild COVID-19 early in the pandemic, 90% still had antibodies 12 months later. But only 51.2% had antibodies that showed neutralizing activity against the original version of the virus and only 44.2% had antibodies that could neutralize the early Alpha variant, the research team at the University of Adelaide reported on medRxiv ahead of peer review.

Neutralizing antibodies against the now-dominant and highly transmissible Delta variant were seen in only 16.2%, with 11.6% against Gamma, and against Beta in only 4.6%.

Survivors of mild COVID-19 “are vulnerable to infection with circulating and newly emerging SARS-CoV-2 variants 12 months after recovery,” the researchers said.

The findings “reinforce the potential benefit” of tailoring vaccine boosters to currently circulating variants, similar to how annual flu vaccines are tailored to current influenza strains, they said.

SOURCE: https://bit.ly/3oGL2k1 medRxiv, online November 11, 2021.

Content Source: https://www.medscape.com/viewarticle/963402?src=rss

The Medical Progress

The Medical Progress is here to provide news for the medical industry on a daily basis which are mainly on the medical cannabis and it’s legalisation.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close